Fc Protein and Glycoengineered Antibodies Market 2016-2021 & 2026 - The Concept of Engineered Antibodies Is Being Widely Used for Development for Biobetters/Biosimilars - Research and Markets

DUBLIN, June 8, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market (2nd Edition), 2016 - 2026" report to their offering.

The study provides a detailed market forecast and opportunity analysis for the short-mid term (2016-2021) and long term (2021-2026). The research, analysis and insights presented in this report include potential sales of the approved drugs and the ones in late stages of development (phase III). To add robustness to our model, we have provided three scenarios for our market forecast; these include the conservative, base and optimistic scenarios.

As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market.

This was done by analyzing:

- The Fc protein and glycoengineered antibody pipeline in terms of phase of development, type of therapy (monotherapy or combination therapy) and target indications.
- Technologies established by various players for development of engineered antibody therapeutics including the key mechanism involved, licencing activity, advantages and the molecules being developed using the technology.
- Partnerships that have taken place in the recent past covering technology licensing, product development and commercialization agreements, clinical trial collaborations, product license agreements, acquisitions and other relevant agreements.
- Inherent threats to growth in the short and long term.
- The likely adoption of the Fc protein and glycoengineered antibodies by understanding the competition posed by the current treatment plans and the expected growth rate over the coming few years.

Example Highlights

- Overall, we have identified nearly 70 products in marketed, clinical and preclinical stages of development; nearly 60% of the pipeline accounts for molecules in clinical development.
- The market is characterized by the presence of both small and big pharma players. Notable examples of small to mid-sized firms include (in alphabetical order) arGEN-X, Celldex Therapeutics, Clovis Oncology, Five Prime Therapeutics, Genmab, Immune Design, MorphoSys, TG Therapeutics and Zymeworks. The larger companies in the domain include Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Roche/Genentech, Kyowa Hakko Kirin and Merck.
- Several firms have also developed their proprietary technologies for Fc optimization and glycoengineering monoclonal antibodies. Examples include (in alphabetical order) BioWa with its POTELLIGENT® technology, Glycart with its GlycoMab Technology, Glycotope with its GlycoExpress, ProBioGen with its GlymaxX® technology and Xencor with its XmAb Fc technology.
- Encouraging clinical results and prospects in multiple disease areas have yielded an intense framework of collaborative and licensing activity in this field. In fact, between 2005 and February 2016, there have been over 80 collaborations in this space.
- With two approved drugs, the glycoengineered antibodies are likely to emerge as the forerunner in the short term (84% of the market share by 2021). Subsequently, the Fc protein engineered antibodies are likely to garner a higher proportion (55% by 2026); specifically, Atezolizumab (by Roche) and Durvalumab (by AstraZeneca/MedImmune) are expected to be blockbusters.
- The overall market is anticipated to grow aggressively at a healthy annual growth rate of over 40% between 2016 and 2026. In the longer term, we expect the market to continue to rise steadily with high adoption rates of marketed drugs and approval of new drugs and indications.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Market Overview

5. Glycoengineered Antibodies Market

6. Fc Engineered Antibodies Market

7. Market Forecast And Opportunity Analysis

8. Technological Platforms For Developing Engineered Antibodies

9. Recent Developments

10. Swot Analysis

11. Conclusion

12. Interview Transcripts

13. Appendix 1: Tabulated Data

14. Appendix 2: List Of Companies And Organizations

- AACR
- AbbVie
- ABN AMRO Capital
- Abramson Cancer Center of the University of Pennsylvania
- Advaxis
- Agensys
- Alexion Pharmaceuticals
- Amgen
- Applied Molecular Evolution
- Arana Therapeutics
- Archimedes Pharma
- arGEN-X
- AstraZeneca
- Avon Breast Cancer Foundation
- Bayer Healthcare
- Berlin-Chemie (Menarini Group)
- Biogen Idec
- BioMedinvest
- BioWa
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cambridge Antibody Technology
- Cancer Research Institute
- Cantargia
- Celgene
- Celldex Therapeutics
- Cellective Therapeutics
- Centocor Research and Development
- Chugai Pharmaceutical
- Clinical Cancer Research
- Columbia University Medical Center
- Committee for Medicinal Products for Human Use
- CSL Limited
- CTI BioPharma
- Cure Brain Cancer Foundation
- Daiichi Sankyo
- Dana-Farber Cancer Institute
- Deutsche Venture Capital
- Eisai
- Eli Lilly
- Eureka Therapeutics
- European Cancer Congress
- European Hematology Association
- Five Prime Therapeutics
- Fondazione Italiana Linfomi ONLUS
- Fountain BioPharma
- Fredrick Manufacturing Center
- GamaMabs Pharma
- Genentech
- Genitourinary Cancers Symposium of the American Society of Clinical Oncology
- Genzyme
- German Breast Group
- German CLL Study Group
- Gilde Investment Management
- GlaxoSmithKline
- Global Life Science Ventures
- GlycArt Biotechnology
- Glycode
- GlycoFi
- Glycotope Biotechnology
- Green Cross
- Greenovation Biotech
- GSK
- GTC Biotherapeutics
- Hoosier Cancer Research Network
- Human Genome Sciences
- Ildong Pharmaceutical
- ImmunoCellular Therapeutics
- Immunocore
- Incyte Corporation
- Inhibrx
- Institute of Cancer Research, United Kingdom
- Italian Network for Tumor Biotherapy Foundation
- Janssen Pharmaceuticals (Johnson & Johnson)
- Johannes Gutenberg University Mainz
- Juno Therapeutics
- Kairos Therapeutics
- KaloBios Pharmaceuticals
- King Faisal Specialist Hospital & Research Center
- Kolltan
- Kyowa Hakko Kirin
- Kyowa Hakko Kogyo
- LFB Biotechnologies
- Lonza
- Ludwig Institute for Cancer Research
- M.D. Anderson Cancer Center
- MacroGenics
- MedImmune
- Memorial Sloan Kettering Cancer Center
- Menarini
- Mentrik Biotech
- Merck
- Merus
- Mirati Therapeutics
- MorphoSys
- Nantes University Hospital
- Naomi Berrie Diabetes Center
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- NCIC Clinical Trials Group
- NEMOD Biotherapeutics
- Neovii Biotech
- National Institutes of Health
- NKT Therapeutics
- NorthWestern University
- Novartis
- Novo Nordisk
- OncoTherapy Science
- Ono Pharmaceutical
- Orpegen Pharma
- Otsuka Pharmaceutical
- Oxford BioTherapeutics
- Parexel
- Peregrine Pharmaceuticals
- Pfizer
- Pharmaceuticals and Medical Devices Agency
- Pharmacyclics
- PRA Health Sciences
- PrECOG
- ProBioGen
- ProStrakan
- Queen Mary University of London
- Quester Capital Management
- Raven Biotechnologies
- Regeneron
- Roche
- Sanofi
- Seattle Genetics
- Servier
- Sidney Kimmel Comprehensive Cancer Center
- Sorrento Therapeutics
- Spectrum Pharmaceuticals
- Swiss Federal Institute of Technology
- Synimmune
- Synthon
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- TG Therapeutics
- Tiziana Life Sciences
- Tizona Therapeutics
- Tolerance Therapeutics
- UCB Pharma
- United Therapeutics
- University of Bern
- University of California, San Diego
- Ventana Medical Systems
- VentiRx Pharmaceuticals
- Xencor
- Zymeworks

For more information visit http://www.researchandmarkets.com/research/5d66nv/fc_protein_and

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[e-mail]

For E.S.T Office Hours Call [phone]
For U.S./CAN Toll Free Call [phone]
For GMT Office Hours Call [phone]

U.S. Fax: [phone]
Fax (outside U.S.): [phone]